Latest Comments

Carefully stepping away from RCTS: clinical trial design in a new medical era

Carefully stepping away from RCTS: clinical trial design in a new medical era

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Insulin-related therapy: despite advances, unmet needs remain

Insulin-related therapy: despite advances, unmet needs remain

Fecal transplant-based treatment for C. difficile reaches phase III trials

Fecal transplant-based treatment for C. difficile reaches phase III trials

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Get Granular, Beat Cancer

Get Granular, Beat Cancer

The Three-Pronged Strategy to Combat NASH

The Three-Pronged Strategy to Combat NASH

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Beyond the indefinite treatment of chronic lymphocytic leukemia

Beyond the indefinite treatment of chronic lymphocytic leukemia

Unmet needs in melanoma treatment

Unmet needs in melanoma treatment

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

AbbVie impresses with solid clinical data for its newest DAA regimen

AbbVie impresses with solid clinical data for its newest DAA regimen

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

Hope for sufferers with extremely rare form of liver cancer

Hope for sufferers with extremely rare form of liver cancer

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

FOURIER outcomes data highlights the importance of value in drug development

FOURIER outcomes data highlights the importance of value in drug development

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

Aurinia poised to independently commercialise voclosporin in lupus nephritis

Aurinia poised to independently commercialise voclosporin in lupus nephritis